On October 5, 2022 AIGEN Sciences, an artificial intelligence (AI)-based new drug development company, reported that it had completed attracting 4.2 billion won in investment through pre-Series A (Press release, AIGEN Sciences, OCT 5, 2022, View Source [SID1234643559]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Partners Investment, Blue Point Partners, Medytox Venture Investment, Quad Asset Management, and Korea University Technology Holdings participated in this investment.
Eisen Science will use this investment to advance artificial intelligence technology by expanding the virtual transcriptome map and to build an integrated platform including transcriptome/structure-based linked molecular design technology. In addition, the company plans to accelerate the development of its own anticancer drug and rare disease pipeline and recruit additional artificial intelligence, synthesis, and pharmacology/bio research personnel.
Eisen Science is an artificial intelligence (AI)-based new drug development company founded by Professor Jae-Woo Kang of Korea University in April last year. Eisen Science’s core new drug development artificial intelligence platform is an artificial intelligence technology based on transcriptome data, which can be used to screen and design drugs with new structures that induce transcriptome changes similar to knock down expression of disease targets. .
The company explained that transcriptome change-inducing drugs have the advantage of minimizing side effects caused by off-target effects of drugs, and can be applied to the development of treatments for intractable diseases for which the disease target is unknown by using the patient’s transcriptome information. am.
Jaewoo Kang, CEO of Eisen Science, said, "Through this investment, we plan to accelerate the development of our own new drug pipeline," adding, "We will develop lead substances in at least three pipelines by 2023 and create business development results with domestic and foreign pharmaceutical companies." "It is planned," he said.
Meanwhile, Igen Science has Vice President (CSO) Gwang-Ok Lee, who has been conducting research for 27 years at domestic pharmaceutical companies such as Hanmi Pharmaceutical, Bukwang Pharmaceutical, and Youngjin Pharmaceutical, and is in charge of planning, business development, and strategic partnerships for over 20 years at pharmaceutical companies such as SK Biopharmaceuticals, Chong Kun Dang, and Boryung. Vice President Kim Jong-ho (CBO) and others were recruited.